Literature DB >> 12198617

Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure.

Alvaro J Romanha1, Rosana O Alves, Silvane M F Murta, João S Silva, Catherine Ropert, Ricardo T Gazzinelli.   

Abstract

Studies in humans and in experimental models suggest the involvement of the immune system for efficacy of drug treatment against protozoan parasites. This study tested this hypothesis by using various cytokine and inducible nitric oxide synthase (iNOS) knockout (KO) mice infected with Trypanosoma cruzi and treated with benznidazole. In contrast with the 100% parasitologic cure rate achieved in wild-type animals, benznidazole failed to cure 100%, 42%, 35%, and 28% of interferon-gamma, interleukin-12 (protein 40), protein 55-tumor necrosis factor receptor, and iNOS KO mice, respectively. These results suggest that activation of the immune system by the parasite and endogenous interferon-gamma play a major role in the efficacy of benznidazole against infection with T. cruzi.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198617     DOI: 10.1086/342415

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Methodological advances in drug discovery for Chagas disease.

Authors:  Juan M Bustamante; Rick L Tarleton
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

4.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Authors:  Adriana M C Canavaci; Juan M Bustamante; Angel M Padilla; Cecilia M Perez Brandan; Laura J Simpson; Dan Xu; Courtney L Boehlke; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

6.  Modulation of autoimmunity by treatment of an infectious disease.

Authors:  Kenneth V Hyland; Juan S Leon; Melvin D Daniels; Nick Giafis; LaKitta M Woods; Thomas J Bahk; Kegiang Wang; David M Engman
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

7.  Resolvin D1 Administration Is Beneficial in Trypanosoma cruzi Infection.

Authors:  Aline L Horta; Tere Williams; Bing Han; Yanfen Ma; Ana Paula J Menezes; Vincent Tu; André Talvani; Louis M Weiss; Huan Huang
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

8.  Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

Authors:  Juan M Bustamante; Lisa M Bixby; Rick L Tarleton
Journal:  Nat Med       Date:  2008-04-20       Impact factor: 53.440

9.  Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.

Authors:  Paola Carolina Bazán; María Silvina Lo Presti; Héctor Walter Rivarola; María Fernanda Triquell; Ricardo Fretes; Alicia Ruth Fernández; Julio Enders; Patricia Paglini-Oliva
Journal:  Parasitol Res       Date:  2008-05-31       Impact factor: 2.289

10.  Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.